Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept
Jill C Krisl1, Rita R Alloway, Adele Rike Shields
11 Work created as Transplant Pharmacy Fellow, Department of Surgery, Division of Transplantation, University of Cincinnati Academic Health Center, Cincinnati, OH 2 Transplant Clinical Research, University of Cincinnati Medical Center, Cincinnati, OH 3 Transplant Clinical Pharmacy, The Christ Hospital, Cincinnati, OH 4 Director of Kidney Transplantation, The Christ Hospital, Kidney and Hypertension Center, Cincinnati, OH 5 Director Division of Transplantation Department of Surgery, University of Cincinnati Medical Center, Cincinnati, OH.
No abstract available in PubMed .
More Related Videos
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tumor Immunotherapy
